Abbott Laboratories (ABT) FCF Payout Ratio: 57.78%
Is Abbott Laboratories’s FCF payout ratio high or low?
Abbott Laboratories's FCF payout ratio of 57.78% is 12% above its 5-year average of 51.75%, around the middle of its 5-year range (37.03%–70.29%).
The FCF payout ratio for Abbott Laboratories (ABT) is 57.78%. It is below its 12-month average by 0.43% (58.03%).
ABT FCF Payout Ratio Chart
ABT Average FCF Payout Ratio Chart
ABT Current vs Average FCF Payout Ratio Chart
ABT FCF Payout Ratio Metrics
FCF PAYOUT RATIO
57.78%
FCF PAYOUT RATIO AVG TTM
58.03%
FCF PAYOUT RATIO AVG 3Y
57.19%
FCF PAYOUT RATIO AVG 5Y
51.75%
FCF PAYOUT RATIO AVG 10Y
54.05%
FCF PAYOUT RATIO AVG 15Y
50.18%
FCF PAYOUT RATIO AVG 20Y
48.59%
CURRENT VS TTM AVG
-0.43%
CURRENT VS 3Y AVG
+1.04%
CURRENT VS 5Y AVG
+11.65%
CURRENT VS 10Y AVG
+6.90%
CURRENT VS 15Y AVG
+15.14%
CURRENT VS 20Y AVG
+18.91%
Payout Ratio Comparison
FCF Payout Ratio
57.8%
Earnings Payout Ratio
65.2%
Dividend Yield
2.75%
FCF Yield
4.76%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $7.39B | $4.12B | 55.7% |
| 2024 | $6.35B | $3.84B | 60.4% |
| 2023 | $5.06B | $3.56B | 70.3% |
| 2022 | $7.80B | $3.31B | 42.4% |
| 2021 | $8.65B | $3.20B | 37.0% |
| 2020 | $5.72B | $2.56B | 44.7% |
| 2019 | $4.50B | $2.27B | 50.5% |
| 2018 | $4.91B | $1.97B | 40.2% |
| 2017 | $4.43B | $1.85B | 41.7% |
| 2016 | $2.08B | $1.54B | 73.9% |
| 2015 | $1.86B | $1.44B | 77.7% |
| 2014 | $2.60B | $1.34B | 51.7% |
| 2013 | $2.18B | $882.00M | 40.5% |
| 2012 | $7.52B | $3.18B | 42.3% |
| 2011 | $7.48B | $2.94B | 39.3% |
| 2010 | $7.72B | $2.67B | 34.6% |
| 2009 | $6.19B | $2.41B | 39.0% |
| 2008 | $6.06B | $2.17B | 35.9% |
| 2007 | $3.53B | $1.96B | 55.5% |
| 2006 | $3.99B | $1.78B | 44.5% |
| 2005 | $3.97B | $1.69B | 42.5% |
| 2004 | $3.12B | $1.60B | 51.3% |
| 2003 | $2.50B | $1.52B | 60.6% |
| 2002 | $2.89B | $1.43B | 49.5% |
| 2001 | $2.40B | $1.27B | 52.9% |
| 2000 | $2.06B | $1.15B | 55.5% |
| 1999 | $1.95B | $1.00B | 51.4% |
| 1998 | $1.49B | $891.70M | 59.8% |
| 1997 | $1.42B | $809.60M | 57.0% |
| 1996 | $1.43B | $728.10M | 50.8% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Abbott Laboratories FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories FCF Payout Ratio FAQ
- What is the FCF payout ratio for Abbott Laboratories (ABT)?
- The FCF payout ratio for ABT stock is 57.78%.
- Is Abbott Laboratories's FCF payout ratio high or low?
- Abbott Laboratories's FCF payout ratio of 57.78% is 12% above its 5-year average of 51.75%, around the middle of its 5-year range (37.03%–70.29%).
- What is the TTM average FCF payout ratio for Abbott Laboratories (ABT)?
- The TTM average FCF payout ratio for ABT stock is 58.03%.
- What is the 3Y average FCF payout ratio for Abbott Laboratories (ABT)?
- The 3Y average FCF payout ratio for ABT stock is 57.19%.
- What is the 5Y average FCF payout ratio for Abbott Laboratories (ABT)?
- The 5Y average FCF payout ratio for ABT stock is 51.75%.
- What is the 10Y average FCF payout ratio for Abbott Laboratories (ABT)?
- The 10Y average FCF payout ratio for ABT stock is 54.05%.
- What is the 15Y average FCF payout ratio for Abbott Laboratories (ABT)?
- The 15Y average FCF payout ratio for ABT stock is 50.18%.
- What is the 20Y average FCF payout ratio for Abbott Laboratories (ABT)?
- The 20Y average FCF payout ratio for ABT stock is 48.59%.
Abbott Laboratories FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 55.66% |
| 2024-12-31 | 60.40% |
| 2023-12-31 | 70.29% |
| 2022-12-31 | 42.40% |
| 2021-12-31 | 37.03% |
| 2020-12-31 | 44.72% |
| 2019-12-31 | 50.47% |
| 2018-12-31 | 40.24% |
| 2017-12-31 | 41.69% |
| 2016-12-31 | 73.92% |
| 2015-12-31 | 77.75% |
| 2014-12-31 | 51.66% |
| 2013-12-31 | 40.48% |
| 2012-12-31 | 42.33% |
| 2011-12-31 | 39.29% |
| 2010-12-31 | 34.60% |
| 2009-12-31 | 39.03% |
| 2008-12-31 | 35.90% |
| 2007-12-31 | 55.54% |
| 2006-12-31 | 44.52% |
| 2005-12-31 | 42.51% |
| 2004-12-31 | 51.34% |
| 2003-12-31 | 60.64% |
| 2002-12-31 | 49.47% |
| 2001-12-31 | 52.88% |
| 2000-12-31 | 55.52% |
| 1999-12-31 | 51.44% |
| 1998-12-31 | 59.84% |
| 1997-12-31 | 57.05% |
| 1996-12-31 | 50.81% |
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford